Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Double-blind Placebo-controlled Trial of CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Cancer

NCT00932724 is registered in ClinicalTrials.gov with Cytavis Biopharma GmbH as lead sponsor.

NCT NCT00932724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00932724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Double-blind Placebo-controlled Trial of CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Cancer
Lead sponsor
Cytavis Biopharma GmbH
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2009
Completion date
August 31, 2012
Enrollment
77 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer